News | November 20, 2007

New LVAD Testing in 10 U.S. Hospitals

November 21, 2007 - Ventracor announced 10 U.S. hospitals have implanted at least one VentrAssist left ventricular assist device (LVAD) as part of its U.S. clinical trials, as part of the company’s strategy to penetrate the U.S. VAD market.

The VentrAssist implantable blood pump is designed for long-term use, and the longest duration implant is now over three years. As part of the Company's US Bridge-to-Transplant (BTT) Pivotal Trial, which involves approximately 140 patients, 18 patients have been implanted in the U.S. The trial aims to evaluate the safety and efficacy of the VentrAssist for short-term use in patients whose heart deteriorates before a donor heart is available for transplant.

Eight patients have been enrolled in the US Destination Therapy (DT) Trial out of approximately 225 enrollments for the trial. The randomized trial is designed to evaluate the safety and efficacy of long-term use of the VentrAssist in patients with heart failure who are not candidates for a heart transplant. There have now been 172 implants at 24 hospitals worldwide, with over 83 years of cumulative patient experience.

The company has developed a new version, the VentrAssist LVA4, which will be introduced in all markets as soon as approval is obtained in response to the regulatory submissions already made.

For more information: www.ventracor.com

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init